Psychotropic drugs are over-used in Australia to control concerning behaviour in people with disability, most of whom have no say in their treatment, the disability royal commission heard.
The commission this week opened hearings into the way people with intellectual disability are treated when they display so-called ‘behaviours of concern’ such as verbal, physical or sexual aggression, self injury and destruction of property.
In his opening statement on Tuesday Chair Ronald Sackville said there appeared to be widespread agreement that psychotropic medications had an important role to play in treating mental illness but could be detrimental if they weren’t appropriately administered.
“There is a clear distinction between using psychotropic drugs appropriately to treat mental illness and administering them to control the behaviour of people with intellectual disability or autism who do not necessarily have any mental illness,” he said.
“In practice, as we shall hear, the distinction is blurred and psychotropic drugs are often used to control challenging behaviour of people with intellectual disability and not truly for the purpose of treating mental illness, although the medical records may suggest otherwise.”
Pschycotropics used as chemical restraints
He said although there are no national statistics, the data that’s available suggests psychotropic drugs are being over-used.
According to the NDIS Qaulity and Safeguards Commission, there were 177,611 reports of unauthorised use of chemical restraints on NDIS participants in 2019-2020, he said.
Senior Counsel Assisting Kate Eastman SC said the use of psychotropic medication as a chemical restraint raised many concerns, including over-reliance on drugs as first resort and the risk of misuse, overdosing and side effects.
The research suggests that up to 60 per cent of people with intellectual disability are prescribed psychotropic medication to manage challenging behaviour, she told the commission.
Loss of research funds
The commission also heard during the week that there has been international concern about over-prescription of psychotropic medication for at least 30 years, and that there is no strong evidence base for the use of many of the psychotropics given to people with intellectual disability.
It also heard that monitoring of psychotropic medications is poor and that there are no standards and and scant guidance on how to go about it.
The Commission heard there is a need for ongoing research into prescribing practices, including off-label and PBS implications and the methods to support and encourage de-prescription of psychotropic medications.
However, some researching funds had been lost during the rollout of the NDIS.
Steps were being taken to agree on principles for nationally consistent authorisation of restrictive practices, NDIS commissioner Graeme Head told the commission.
You can follow Community Care Review on Facebook, Twitter and LinkedIn and you can sign up to our CCR newsletter which will be delivered to your inbox once a week. Keep up with the latest news by visiting our website.